Fred Saad, MD

Articles by Fred Saad, MD

Hitting Hard and Early: Using Radioligand Therapy Earlier in mHSPC

June 3rd 2026

Fred Saad, MD, FRCS, CQ, FCAHS, discussed the clinical benefits of introducing lutetium Lu 177-PSMA-617 earlier to delay progression to mCRPC.

Abiraterone and olaparib continued to demonstrate a positive trend in overall survival (OS) in patients with metastatic castration-resistant prostate cancer, according to Fred Saad, MD, FRCS, though he stated that longer follow-up is needed to confirm the benefit.

Fred Saad, MD, FRCS, Highlights Positive OS Trend With Abiraterone and Olaparib in mCRPC But Cites Need for Longer Follow-up

ByFred Saad, MD

September 22nd 2022

Abiraterone and olaparib continued to demonstrate a positive trend in overall survival (OS) in patients with metastatic castration-resistant prostate cancer, according to Fred Saad, MD, FRCS, though he stated that longer follow-up is needed to confirm the benefit.

Latest Updated Articles

Hitting Hard and Early: Using Radioligand Therapy Earlier in mHSPC
June 3rd 2026
Fred Saad, MD, FRCS, Highlights Positive OS Trend With Abiraterone and Olaparib in mCRPC But Cites Need for Longer Follow-up
September 22nd 2022

Fred Saad, MD

Articles by Fred Saad, MD

Hitting Hard and Early: Using Radioligand Therapy Earlier in mHSPC

Fred Saad, MD, FRCS, Highlights Positive OS Trend With Abiraterone and Olaparib in mCRPC But Cites Need for Longer Follow-up

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Palbociclib Combo in HR+, HER2+ Metastatic Breast Cancer

Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications

NCCN Updates Bladder Cancer Guidelines for ctDNA MRD Testing

EU Approves Enfortumab Vedotin/Pembrolizumab in Cisplatin-Ineligible MIBC

Offering Hope and Support Towards The Cancer Survivorship Journey